Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Assessing risk of bias in randomized controlled trials of methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)

Texto completo
Autor(es):
Rodrigues-Tartari, Raissa [1] ; Swardfager, Walter [2, 3, 4] ; Salum, Giovanni A. [5] ; Rohde, Luis A. [5] ; Cogo-Moreira, Hugo [1]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Univ Fed Sao Paulo, Dept Psychiat, Rua Borges Lagoa 570, First Floor, BR-04038000 Sao Paulo - Brazil
[2] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON - Canada
[3] Sunnybrook Res Inst, Hurvitz Brain Sci Program, Toronto, ON - Canada
[4] Toronto Rehabil Inst, Univ Hlth Network, Toronto, ON - Canada
[5] Univ Fed Rio Grande do Sul, Dept Psychiat, Porto Alegre, RS - Brazil
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH; v. 27, n. 1 MAR 2018.
Citações Web of Science: 5
Resumo

To test how reliable the tool recommend by Cochrane Collaboration for assessing risk of bias systematic reviews of randomized clinical trials is in the context of methylphenidate for children and adolescents with attention deficit hyperactivity disorder. Confirmatory factor analysis was used to evaluate a unidimensional model for the 7 indicators, applied to 184 Randomized Clinical Trial (RCTs) within a 2015 Cochrane systematic review titled Methylphenidate for children and adolescents with attention deficit hyperactivity disorder. A unidimensional model resulted in excellent adequacy indices, but only 2 indicators had very high factor loadings and low measurement errors. In terms of content, the 7 indicators showed poor reliability (=0.642); however, the set of indicators was precise in evaluating studies with a high amount of bias risk. The Cochrane model of risk of bias as it is, exhibited good fit indices but the majority of the items were not reliable to adequately capture risk of bias in the context of clinical trials of methylphenidate for ADHD. (AU)

Processo FAPESP: 16/08208-8 - Avaliando os riscos de vieses em ensaios clínicos randomizados sobre metilfenidato em transtorno de déficit de atenção/hiperatividade: aplicação da análise fatorial confirmatória
Beneficiário:Raissa Rodrigues Tartari
Linha de fomento: Bolsas no Brasil - Iniciação Científica